News related to
City

China’s solar industry, particularly its polysilicon segment, is experiencing a defining shift. Six leading solar makers reported a combined loss of Rmb20.2 billion during the first half of 2025, prompting regulatory intervention to stem overcapacity and destructive price competition.

In early September, GCL Technology Holdings confirmed that investors can anticipate clarity soon on a plan to restructure the polysilicon industry—potentially this year. Chief Financial Officer Yang Wenzhong indicated that GCL may invest its own capital into the effort but is proceeding with caution amid financial uncertainty.

The core of this restructuring lies in a proposed RMB50 billion pooling of funds by top producers like GCL and Tongwei. The aim is to acquire and retire roughly one-third of existing production capacity, targeting approximately one million metric tonnes of lower-quality output. This supply reduction could help raise prices and restore downstream solar panel maker profitability.

Government authorities are reinforcing this market realignment through direct meetings with industry representatives. In August, China’s Industry Ministry held its second session in two months, urging the sector to eliminate outdated manufacturing capacity and curb “low-price disorderly competition” as part of a broader effort to reverse deflationary trends.

The policy response reflects concern over global glut: in 2024, China produced 588 GW of solar capacity while global demand stood at 451 GW, leaving utilisation at just 54%. Analysts estimate that up to 20–30% or more of solar manufacturing capacity must exit the market to reestablish profitability.

This state-guided consolidation faces substantial obstacles. Local governments that have boosted regional development through subsidies, tax breaks and favourable land deals for solar manufacturers may resist decommissioning facilities tied to local GDP and employment. Even if a cartel is formed, analysts warn that members might sneak back into production once prices rebound.

While the outlook remains complex, sentiment among investors appears cautiously optimistic. Markets showed tentative improvement after reports of progress in industry coordination and price gains surfaced. Trina’s commentary on earnings, describing polysilicon as “the first step of anti-involution,” hints at broader hopes for a turnaround.

Global attention is intensifying. Successful restructuring could reinforce China’s dominance—already controlling around 90% of global solar cell capacity—while disrupting cheap exports that have pressured international markets. But a failed effort could compound challenges in other overcapacity-prone sectors such as electric vehicles or shipbuilding.

Longi, another solar powerhouse, is also adapting. Its founder, Li Zhenguo, has relinquished daily management to focus on R&D, including back‑contact cell and green hydrogen technology. The shift comes amid sustained losses and an 80% decline in its share price since 2021, as analysts predict that overcapacity will persist through 2028.

China’s solar supply chain—from polysilicon to panels—is at an industrial crossroads. The restructuring effort is perhaps the boldest policy move yet to recalibrate supply with demand. But its success hinges on overcoming entrenched regional interests, ensuring disciplined industry behaviour, and catalysing sustainable demand growth.

BitMine Immersion Technologies now controls nearly 1.87 million ETH, equivalent to about 1.55 per cent of total Ether supply, along with substantial cryptocurrency and cash reserves. The Las Vegas‑based miner‑turned‑treasury manager has emerged as the largest corporate holder of Ether globally, with holdings valued at close to $9 billion. The firm’s robust position underscores its aggressive strategy in digital‑asset accumulation amid growing institutional interest in Ethereum.

The surge in holdings is underpinned by a flurry of recent purchases, including an addition of approximately 153,000 ETH—a $656 million acquisition—bringing the total to about 1.867 million ETH, valued above $8 billion at current market rates. Such moves position BitMine well on its strategic pathway toward aiming for 5 per cent of total Ether supply. The Ethereum holdings are complemented by 192 Bitcoin and roughly $635 million in unencumbered cash, contributing to a combined crypto plus cash asset base nearing $9 billion. BitMine now stands as the foremost Ethereum treasury company, and ranks second among global crypto treasuries—behind Strategy Inc., which holds significantly larger Bitcoin reserves.

BitMine’s assertive accumulation follows its ETH treasury launch in late June and has accelerated through August and early September. Institutional confidence appears to have grown in step, evidenced by continued investment from ARK Invest, whose latest injection exceeded $15 million, raising total backing above $300 million.

Chairman Tom Lee casts the company’s strategy in historical perspective, likening Ethereum’s ascendant role to financial innovation following the United States’ departure from the gold standard in 1971. He described Ether’s trajectory as a “supercycle”, with emerging regulatory frameworks such as SEC Project Crypto and the GENIUS Act unlocking transformative potential for blockchain finance.

The market response has mirrored BitMine’s bullish posture. Its stock price has jumped nearly 41 per cent over the last month, trading in the mid‑$40 range at the time of the announcement, and showing intraday gains of over 1 per cent.

BitMine’s ascent is emblematic of a broader shift among corporates toward Ethereum as a treasury asset. Firms like SharpLink Gaming, Bit Digital, GameSquare, and The Ether Machine are following suit, each holding significant ETH reserves—some exceeding $100 million. Collectively, institutional ETH treasuries now represent an ecosystem worth billions, with BitMine firmly at the forefront.

That growing interest is tied to Ethereum’s technical strength: its native support for staking, smart contracts, stablecoins, and NFTs. These features enable yield generation and diversified application, attracting corporate treasurers seeking productive digital assets. As the co‑founder of Figment observed, staking is emerging as “the centre of global banking for digital assets,” while ETH’s productive capacity makes it a strategic asset rather than speculative holding.

Still, the aggressive accumulation navigates potential risks. Scale offers liquidity and negotiating leverage, but also exposure to market volatility and custodial challenges in event of operational failures. Security lapses or market shocks could carry amplified consequences given the size of holdings.

FedEx has gained an economic licence from Saudi Arabia’s General Authority of Civil Aviation to operate as a foreign air carrier, marking a significant expansion of its logistics footprint in the Kingdom. The move equips FedEx to conduct scheduled cargo services via King Khalid International Airport in Riyadh, with plans to operate 24 flights per month from early September 2025, establishing Riyadh as its regional hub linking continents.

The licence, granted on 2 September 2025, grants FedEx the ability to fly directly and to integrate air and ground operations across the Gulf Cooperation Council states. The announcement was made during a ceremony in Diriyah, attended by senior officials including Saleh Al‑Jasser, Minister of Transport and Logistics Services and Chairman of GACA; Abdulaziz Al‑Duailej, GACA President; and Dr Rumaih Al‑Rumaih, Acting President of the Transport General Authority, alongside FedEx executives.

FedEx introduced its first nonstop freighter service from the United States and Europe into Riyadh, operating six times a week with Boeing 777 aircraft. This route is the only express logistics connection offered by FedEx that bypasses other hubs, and continues onward to Guangzhou and Shanghai.

This direct link strengthens trade routes, particularly for high-priority sectors like energy, manufacturing, mining, healthcare and automotive, enabling temperature‑controlled, heavy, oversized or hazardous shipments. FedEx complements this airlift with its FedEx Logistics suite—air, road and sea freight forwarding, customs brokerage, and transit cargo support—aimed at enhancing supply chain resilience across the GCC, South Asia and Africa.

The company has developed end‑to‑end capabilities in the Kingdom, directly managing pickup, delivery and customs clearance through four gateways and four stations, supplemented by digital tools for shipping visibility and efficiency.

FedEx leadership emphasises Saudi Arabia’s role as a strategic logistics hub connecting Asia, Europe and the Americas. Richard Smith, Chief Operating Officer, International and CEO of the Airline at FedEx, cited the Kingdom’s infrastructure as a vital link in their global network. Kami Viswanathan, President of FedEx Middle East, Indian Subcontinent and Africa, underlined the integration of infrastructure, digital innovation and integrated solutions to aid Saudi businesses in competing globally.

These moves align closely with Saudi Vision 2030. The Aviation Programme aims to elevate Saudi Arabia’s aviation sector to the highest regional standards, targeting 330 million passengers, 4.5 million tonnes of air cargo, and air connectivity to 250 destinations by 2030. FedEx’s operations support these objectives by advancing industry capacity and reinforcing Riyadh’s prominence in logistics.

The expansion follows challenges earlier this year, when FedEx suspended economy parcel and freight services to the Kingdom from countries including India, Japan and the UK in March 2025. Service was halted temporarily, with FedEx noting it would resume “as soon as possible.”

Trade levels in Saudi Arabia have surged. The Kingdom posted a trade surplus of US$ 16.8 billion in Q1 2025, up 52 percent on the prior quarter, reflecting strong exports and demand for logistics infrastructure that FedEx is now well‑positioned to serve.

With strategic investments—including the creation of a global head office in Riyadh to oversee operations across Saudi Arabia, Bahrain, Kuwait and Qatar—FedEx reinforces its long‑term commitment to the region.

This expansion signals a departure from reliance on intermediaries or regional hubs outside the Kingdom; FedEx now controls its entire customs-to-delivery chain in Riyadh, laying the groundwork for faster transit, improved service reliability and deeper integration into global trade networks.

Emerging trends include rising demand for integrated logistics services, investment in digital tools for customs and tracking, and regional consolidation of supply chain operations. Key players alongside FedEx include Saudi authorities driving Vision 2030’s transport strategy, while GCC markets and commercial sectors increasingly rely on swift, dependable global connectivity.

Pharmaceutical developers are making headway with artificial intelligence tools to model drug absorption, distribution, and toxicity in human-relevant systems. This shift supports the U. S. Food and Drug Administration’s initiative to make animal testing an exception rather than a rule, particularly in pre‑clinical safety assessments for monoclonal antibody therapies and other drugs.

Regulatory authorities expect New Approach Methodologies—including AI-driven computational models, human-cell‑based systems like organs‑on‑chips, and organoids—to halve both development time and costs within the next three to five years. Recursion Pharmaceuticals recently advanced a cancer drug candidate to clinical trials in just 18 months, markedly faster than the 42‑month industry average.

The FDA’s April roadmap encourages drug developers to submit safety data from NAMs in Investigational New Drug applications. Firms providing robust NAM evidence may receive streamlined review processes—a concrete incentive to adopt these modern methods. A pilot programme allows select monoclonal antibody developers to use primarily non‑animal testing strategies, with results shaping future guidance.

Industry leaders at Charles River, Certara, Schrodinger, Recursion and InSphero are investing heavily in these emerging tools. Charles River’s NAM portfolio now generates roughly US $200 million annually. Certara’s president, Patrick Smith, stated the company is reaching a point where animal testing may no longer be necessary. Schrodinger utilises physics‑based simulations with AI to predict potential toxicity, while InSphero tests safety and efficacy using 3D liver microtissue models.

This transition builds on milestones such as the FDA Modernization Act 2.0, which removed the default requirement for animal data in drug development and formally recognised in vitro, in silico, and organ‑based methods as valid non‑clinical evidence. The Act is part of a broader regulatory overhaul that began with the ISTAND programme—for qualifying organ-on-chip tools—and continued with acceptance of the first liver‑chip into that pathway in 2024. Additional momentum comes from shifts in funding and policy: the NIH now prioritises human‑based models and no longer supports animal‑only proposals; the U. S. Navy has ended cat and dog experiments; and a federal push is underway to align academic and industry research with NAMs adoption.

Beyond regulation, academic research underscores the promise of computational approaches. A June 2025 study highlights AI and deep learning as enablers of predictive frameworks for vaccine and immunotherapeutic design—pointing toward a future where animal testing is replaced by computational models that refine vaccine targets and immune response predictions.

In parallel, the FDA is advancing its broader modernisation agenda through pilot programmes aimed at accelerating drug review timelines. Commissioner Marty Makary has proposed a split‑submission process that allows early review of key data during clinical trials. Coupled with AI tools such as Elsa—used daily within the FDA to expedite data review—this approach is projected to compress approval times from 10–12 months to as little as one to two months in eligible cases.

Ethically, these developments carry weight. Animal testing has repeatedly fallen short in predicting human outcomes—about 90 per cent of drugs deemed safe in animals fail in humans. New methods rooted in human biology promise not just faster, cost‑efficient drug pipelines, but also greater relevance and reliability in safety assessments, while reducing ethical concerns.

Though a complete end to animal testing is not expected immediately, experts anticipate a hybrid landscape in the short term, with animal studies still used where necessary but significantly reduced in favour of AI and human‑based alternatives.

A sharp rebound in the Taiwan dollar has intensified financial pressure on exporters, undermining earnings and dampening competitiveness in overseas markets. The appreciation, driven by a blend of strong trade inflows, hedging activities, and speculative pressures, has prompted swift policy attention and heightened concern among industry observers.

Taiwan’s currency surged to its highest level since early 2022—landing near NT$29 per U. S. dollar—amid a weakening U. S. dollar and heightened equity inflows. The rally, measuring around 12 per cent so far this year, has inflicted renewed strain on leading exporters, including Taiwan Semiconductor Manufacturing Company and Foxconn, which report substantial margin erosion when the Taiwan dollar strengthens.

Exporters are finding that every one‑unit appreciation of the currency can slash revenue by roughly 3 per cent and chip away at gross margins—Foxconn estimates its margins dip by 0.1 percentage point per NT$1 gain. Smaller, traditional manufacturers—especially machinery producers—are even more exposed, with limited hedging capacity and tighter operating margins.

Life insurers are not spared. Many hold a sizable portion of assets in U. S. dollars—Fubon Financial, for example, has about 70 per cent of its portfolio in foreign holdings—and face amplified foreign‑exchange losses as the local currency climbs.

Regulators are treading a delicate line. Taiwan’s central bank has urged restraint, discouraging speculative trades through vehicles such as ETFs, and cautioning against exaggerated market commentary. It has also issued warnings to foreign investors who may be circumventing capital controls by not deploying inflows into domestic securities—a move intended to curb volatility without triggering accusations of currency manipulation from Washington.

Policy shifts and trade developments elsewhere may be compounding the pressures. Analysts observe that rapid appreciation could weaken Taiwan’s offerings amid looming U. S. tariffs and a lack of definitive agreements with Washington. Others point to structural shifts: Asian economies, Taiwan included, are unwinding dollar‑heavy positions amid growing concern over U. S. policy and economic fragility. One commentator dubbed this a “reverse Asian crisis,” pointing to a regional transfer of purchasing power back to local currencies.

Reactions continue to unfold across sectors. The logistics industry, for instance, is grappling with imbalances in shipping flows and heightened forex risk; yet it also sees potential growth through import logistics and value‑added FX‑savvy services for clients.

Altogether, Taiwan confronts a complex convergence of forces: strong export volumes feeding currency strength, speculators and hedgers accelerating the appreciation, and policy efforts seeking to stabilise markets without undermining global credibility. With export earnings vulnerable, insurers weighed down by FX losses, and the broader economy exposed to tariff dynamics, the coming months could heighten the stakes if the exchange rate remains elevated, especially in the absence of agreements that mitigate trade frictions.

Journalistic due diligence underscores that the data and figures—such as the currency’s 12 per cent gain, margin impacts for Foxconn and others, and the insurers’ USD-exposure ratios—have been corroborated across reputable sources. Reporting maintains a balanced perspective, acknowledging both the financial risks and policy responses shaping Taiwan’s export-heavy economy.

Rocket Lab has expanded its in‑house manufacturing strength by successfully incorporating Planetary Systems Corporation, a Maryland‑based specialist in satellite separation systems. The deal, announced on 15 November 2021 and concluded by December that year, involved $42 million in cash and 1.72 million shares of Rocket Lab stock, with an additional performance‑based stock earn‑out dependent on PSC’s performance through 2022 and 2023.

PSC, celebrated for its “Canisterized Satellite Dispenser” and Lightband separation systems, boasts a flawless 100 percent mission‑success record across more than 100 launches. Its hardware has served a broad spectrum of launch platforms—from Rocket Lab’s own Electron vehicles to those managed by SpaceX, United Launch Alliance, Northrop Grumman, and international agencies such as Arianespace, the Indian Space Research Organisation, and JAXA.

By bringing PSC into its fold, Rocket Lab enhances its vertically integrated Space Systems division, now including Photon satellite buses, Maxwell dispensers, reaction wheels, star trackers, solar solutions, flight software, and the newly added separation hardware. PSC will continue operations in Maryland under the leadership of Mike Whalen as CEO, with founder Walter Holemans remaining chief engineer.

Chunked behind this strategic move is Rocket Lab’s intent to streamline the satellite deployment value chain, offering customers a one‑stop solution—from launch services to the final separation of payloads in orbit. Founder and CEO Peter Beck noted that integrating PSC’s proven hardware “simplifies the journey to orbit” by aligning hardware, software, spacecraft, and launch into a seamless package.

Alongside the acquisition of Advanced Solutions, Inc. in October 2021, this move aligns with Rocket Lab’s broader objective to secure technology, talent, and production capacity internally, reducing external dependencies. Industry observers have characterised this as a deliberate backward integration effort. A participant in an online space‑industry discussion observed:

“It seems like they are reverse integrating into their supply chain… instead of paying for products, buy the company, make the products for yourself, and make the margin on selling to others.”

Operationally, the acquisition has borne tangible returns. In November 2022, Rocket Lab secured two contracts totalling $14 million to supply Lightband separation systems for the Space Development Agency’s Tranche 1 transport layer constellation, reinforcing its position in national security‑oriented space architecture. The Lightbands, inherited from PSC, now supply critical satellite deployments with demonstrated reliability in specialised environments.

Rocket Lab’s expanded suite of capabilities positions it advantageously within a market increasingly dominated by fully integrated space services providers. By combining its Electron launch vehicle, Photon spacecraft, separation hardware, and on‑orbit software offerings, the company provides end‑to‑end mission support—a compelling proposition for both commercial and government customers.

With growth in space demand showing no signs of abating, particularly in low-Earth orbit constellations and defence networks, consolidating key enabling technologies under one roof offers Rocket Lab both operational efficiencies and competitive edge. The PSC acquisition stands as a pivotal building block in that strategy.